Record year for Swiss biotech industry
The Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.
EU orders 100 million additional doses from Biontech
COVID-19: Study finds neutralising antibodies to disappear rapidly
A new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
BioVersys gets 20m EIB loan to develop novel antibiotics
Swiss BioVersys has received 20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink 414m IL-17A blocker R&D contract
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Next-gen COVID-19 vaccine good in preclinical tests
Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
EMA: AZD1222 causes serious rare ADEs
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
Targeting SARS-CoV-2 differently
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus main protease.
miRNAs unmask vulnerability in breast cancer stem cells
Researchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Janssen to pledge COVID-19 vaccine to African Union
Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).